Latest news with #Allouche
The Age
a day ago
- Business
- The Age
Interstate buyers swoop to win $1.8m Brunswick house from locals
A newly renovated Victorian house in Brunswick has sold under the hammer for $1,802,000, well beyond its quoted range, after a fierce bidding war at auction on Saturday. The three-bedroom, two-bathroom home at 104 Donald Street was listed with a quoted price range of $1.5 million to $1.6 million, and had a reserve of $1.6 million. Six bidders, a mix of upsizers and downsizers, competed for the property. Bidding opened at $1,525,000, quickly hit the reserve, and then slowed to smaller rises. 'It was a really competitive auction,' said Jamil Allouche from Ray White Brunswick. 'It was fierce at one stage, then it got tentative for a bit, then it got fierce again.' An older couple relocating from interstate secured the home via their daughter, who bid on their behalf. They outbid local downsizers in a showdown Allouche described as 'hammer and tongs'. He said the single-storey layout was a major selling point. 'It is a gorgeous place. It was done really tastefully. The renovation at the back was beautiful. A single level is what attracted the downsizers, and it had a beautiful, gorgeous renovation out the back. And that was the driving force.' Allouche said Brunswick remained in demand with buyers. 'Brunswick is such a melting pot for not only demographics but cultures. [There is also] the transport connection, and you're super-close [to the CBD] ... It has a beautiful vibe. It's just the place to be.'
Sydney Morning Herald
a day ago
- Business
- Sydney Morning Herald
Interstate buyers swoop to win $1.8m Brunswick house from locals
A newly renovated Victorian house in Brunswick has sold under the hammer for $1,802,000, well beyond its quoted range, after a fierce bidding war at auction on Saturday. The three-bedroom, two-bathroom home at 104 Donald Street was listed with a quoted price range of $1.5 million to $1.6 million, and had a reserve of $1.6 million. Six bidders, a mix of upsizers and downsizers, competed for the property. Bidding opened at $1,525,000, quickly hit the reserve, and then slowed to smaller rises. 'It was a really competitive auction,' said Jamil Allouche from Ray White Brunswick. 'It was fierce at one stage, then it got tentative for a bit, then it got fierce again.' An older couple relocating from interstate secured the home via their daughter, who bid on their behalf. They outbid local downsizers in a showdown Allouche described as 'hammer and tongs'. He said the single-storey layout was a major selling point. 'It is a gorgeous place. It was done really tastefully. The renovation at the back was beautiful. A single level is what attracted the downsizers, and it had a beautiful, gorgeous renovation out the back. And that was the driving force.' Allouche said Brunswick remained in demand with buyers. 'Brunswick is such a melting pot for not only demographics but cultures. [There is also] the transport connection, and you're super-close [to the CBD] ... It has a beautiful vibe. It's just the place to be.'
Yahoo
11-03-2025
- Business
- Yahoo
Radiology AI software provider Gleamer expands into MRI with two M&A transactions
Medical imaging is a broad term that encompasses several distinct technologies. After working on AI-powered tools to enhance X-rays and mammographies, French startup Gleamer now aims to tackle magnetic resonance imaging (MRI). Instead of starting from scratch, Gleamer has acquired a startup that has already been working on AI-powered MRI analysis, Caerus Medical, and is merging with Pixyl. Gleamer is part of the second wave of startups trying to improve medical imaging using artificial intelligence. Several tech founders created startups around this topic in 2014 or 2015. While most of them went nowhere, there have been some consolidation in the space. For instance, Zebra Medical Vision and Arterys were both acquired by Nanox and Tempus, respectively. Founded in 2017, Gleamer has been building an AI assistant for radiologists, a sort of copilot for medical imaging. With Gleamer, radiologists can theoretically improve the diagnostic accuracy when interpreting medical images. The startup has already persuaded 2,000 institutions across 45 countries to use its software solution. Overall, Gleamer has processed 35 million examinations. The company has received CE and FDA certifications for its bone trauma interpretation product. In Europe, it also offers products specifically focused on chest X-rays, orthopedic and bone age measurements with CE certification. 'Unfortunately, the one-size-fits-all approach to radiology doesn't work,' Gleamer co-founder and CEO Christian Allouche told TechCrunch. 'It's very complicated to have a large model that covers all medical imaging and delivers the level of performance expected by doctors.' That's why the company created small internal teams focused on mammographies and CT scans. 'Three weeks ago we released our mammography product, which we have been working on for 18 months,' Allouche said. It's based on a proprietary AI model that has been trained on 1.5 million mammographies. 'We have a partnership with Jean Zay, the French government's GPU cluster,' Allouche said. The company is also working on CT scans for cancers. But what about MRI? 'MRI is a different technological space,' Allouche said. 'You have a lot of tasks in MRI. It's not just detection, you've got segmentation, you've got detection, you've got characterization, classification, multi-sequence imaging.' That's why Gleamer is acquiring a small startup (Caerus Medical) and merging with a larger one (Pixyl) to move faster. These two companies have been working in this space for several years. Gleamer isn't disclosing the terms of the deals. 'These two companies will become our two MRI platforms, with the clear ambition of covering all use cases over the next two to three years,' Allouche said. While Gleamer's models show promising results, they are not yet perfect. For example, with the company's new mammography model, the startup claims it can detect four out of five cancers. In comparison, a human radiologist without AI assistance typically identifies cancer in three out of five cases. However, the productivity gains from a tool like Gleamer could radically change medical imaging. A missed tumor is likely to appear in a follow-up exam a few months later. 'In the not-too-distant future, I think we'll all be getting routine whole body MRIs paid for by our insurance companies — since they're not irradiating,' Allouche said. However, in some cities, there are already too few radiologists to meet the demand for reactive imaging. If the industry shifts toward preventive imaging, AI tools will become indispensable. Gleamer's CEO thinks AI could become an 'orchestrating and triaging' tool. Most medical imaging examinations are conducted as a way to rule out some diagnoses. 'So, there's a real need to automate all this with a very solid AI model that has a much higher level of sensitivity than a human,' Allouche said.
